| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
BOSTON—To determine the impact of a potential drug on cell viability, researchers often rely on DNA labeling with a probe such as bromodeoxyuridine followed by fluorescent antibody-based detection. To get the antibodies to the nucleus, however, requires harsh treatments or nuclease digestion that can interfere with multiplexing with secondary probes, according to researchers from Harvard Medical School and Invitrogen's Molecular Probes division. To get around this problem, they replaced both the label and detection molecules.
 
As they explained in a poster at the recent SBS meeting, the researchers labeled DNA with ethynyl-deoxyuridine (EdU), which they detected by fluorescence under mild aqueous conditions using a Cu(I)-catalyzed azide-alkyne cycloaddition reaction with Alexa Fluor 488 azide dye. The new method was capable of monitoring DNA synthesis by imaging adherent cells or by flow cytometry, and could be coupled with a second dye to correlate synthesis with cellular morphology changes.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue